Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials

Atherosclerosis

Volumn 196, Issue 2, 2008, Pages 823-834

  Chan, Doris T ^a,b   Irish, Ashley B ^b   Dogra, Gursharan K ^a,b   Watts, Gerald F ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Chronic kidney disease; Dyslipidaemia; Lipoproteins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BILE ACID SEQUESTRANT; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; PHYTOSTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ARTERY DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DIALYSIS; DRUG DOSE COMPARISON; DRUG EFFICACY; DYSLIPIDEMIA; HEART DEATH; HEART INFARCTION; HEMODIALYSIS; HUMAN; INSULIN RESISTANCE; KIDNEY TRANSPLANTATION; LIPID METABOLISM; METABOLIC SYNDROME X; MONOTHERAPY; MYOPATHY; POST HOC ANALYSIS; PRIORITY JOURNAL; RHABDOMYOLYSIS;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC; LIPIDS; LIPOPROTEINS; NEPHROTIC SYNDROME; PRACTICE GUIDELINES AS TOPIC;

EID: 38349099256     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.01.023     Document Type: Article

References (110)

1. Foley R.N., Parfrey P.S., and Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 (1998) S112-S119
2. Foley R.N., Wang C., and Collins A.J. Cardiovascular risk factor profiles and kidney function stage in the US general population: the NHANES III study. Mayo Clin Proc 80 (2005) 1270-1277
3. Go A.S., Chertow G.M., Fan D., McCulloch C.E., and Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004) 1296-1305
4. Vanholder R., Massy Z., Argiles A., et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 20 (2005) 1048-1056
5. Baigent C., Burbury K., and Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 356 (2000) 147-152
6. Schwarz U., Buzello M., Ritz E., et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 15 (2000) 218-223
7. Blacher J., Guerin A.P., Pannier B., Marchais S.J., and London G.M. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38 (2001) 938-942
8. Blacher J., Safar M.E., Guerin A.P., et al. Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int 63 (2003) 1852-1860
9. London G.M. Arterial function in renal failure. Nephrol Dial Transplant 13 Suppl. 4 (1998) 12-15
10. Vaziri N.D. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 290 (2006) F262-F272
11. Attman P.O., Samuelsson O., Johansson A.C., Moberly J.B., and Alaupovic P. Dialysis modalities and dyslipidemia. Kidney Int Suppl (2003) S110-S112
12. Batista M.C., Welty F.K., Diffenderfer M.R., et al. Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome. Metabolism 53 (2004) 1255-1261
13. Kimak E., Solski J., and Janicka L. Lipoprotein profiles at different stages of chronic renal insufficiency. Ren Fail 22 (2000) 63-71
14. Farbakhsh K., and Kasiske B.L. Dyslipidemias in patients who have chronic kidney disease. Med Clin North Am 89 (2005) 689-699
15. Deighan C.J., Caslake M.J., McConnell M., Boulton-Jones J.M., and Packard C.J. Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis 35 (2000) 852-862
16. Prinsen B.H., De Sain-Van Der Velden M.G., de Koning E.J., et al. Hypertriglyceridemia in patients with chronic renal failure: possible mechanisms. Kidney Int Suppl (2003) S121-S124
17. Cheung A.K., Parker C.J., Ren K., and Iverius P.H. Increased lipase inhibition in uremia: identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma. Kidney Int 49 (1996) 1360-1371
18. Nishizawa Y., Shoji T., Kawagishi T., and Morii H. Atherosclerosis in uremia: possible roles of hyperparathyroidism and intermediate density lipoprotein accumulation. Kidney Int Suppl 62 (1997) S90-S92
19. Weintraub M., Burstein A., Rassin T., et al. Severe defect in clearing postprandial chylomicron remnants in dialysis patients. Kidney Int 42 (1992) 1247-1252
20. Kim C., and Vaziri N.D. Down-regulation of hepatic LDL receptor-related protein (LRP) in chronic renal failure. Kidney Int 67 (2005) 1028-1032
21. Vaziri N.D., Liang K., and Parks J.S. Down-regulation of hepatic lecithin:cholesterol acyltransferase gene expression in chronic renal failure. Kidney Int 59 (2001) 2192-2196
22. Kurella M., Lo J.C., and Chertow G.M. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 16 (2005) 2134-2140
23. Prinsen B.H., Rabelink T.J., Romijn J.A., et al. A broad-based metabolic approach to study VLDL apoB100 metabolism in patients with ESRD and patients treated with peritoneal dialysis. Kidney Int 65 (2004) 1064-1075
24. de Sain-van der Velden M., Kaysen G.A., Barrett H.A., et al. Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis. Kidney Int 53 (1998) 994-1001
25. Joven J., Villabona C., Vilella E., et al. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med 323 (1990) 579-584
26. Kaysen G.A., and de Sain-van der Velden M.G. New insights into lipid metabolism in the nephrotic syndrome. Kidney Int Suppl 71 (1999) S18-S21
27. Vaziri N.D. Molecular mechanisms of lipid disorders in nephrotic syndrome. Kidney Int 63 (2003) 1964-1976
28. Wheeler D.C., and Bernard D.B. Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment. Am J Kidney Dis 23 (1994) 331-346
29. Vaziri N.D., and Liang K.H. Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis. Kidney Int 48 (1995) 1979-1985
30. Vaziri N.D., and Liang K.H. Down-regulation of hepatic LDL receptor expression in experimental nephrosis. Kidney Int 50 (1996) 887-893
31. Vaziri N.D., Kim C.H., Phan D., Kim S., and Liang K. Up-regulation of hepatic Acyl CoA: diacylglycerol acyltransferase-1 (DGAT-1) expression in nephrotic syndrome. Kidney Int 66 (2004) 262-267
32. Ordonez J.D., Hiatt R.A., Killebrew E.J., and Fireman B.H. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 44 (1993) 638-642
33. Lechner B.L., Bockenhauer D., Iragorri S., Kennedy T.L., and Siegel N.J. The risk of cardiovascular disease in adults who have had childhood nephrotic syndrome. Pediatr Nephrol 19 (2004) 744-748
34. Liu J., and Rosner M.H. Lipid abnormalities associated with end-stage renal disease. Semin Dialysis 19 (2006) 32-40
35. Fytili C.I., Progia E.G., Panagoutsos S.A., et al. Lipoprotein abnormalities in hemodialysis and continuous ambulatory peritoneal dialysis patients. Ren Fail 24 (2002) 623-630
36. Attman P.O., Samuelsson O.G., Moberly J., et al. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis. Kidney Int 55 (1999) 1536-1542
37. Kolovou G.D., Anagnostopoulou K.K., and Cokkinos D.V. Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad Med J 81 (2005) 358-366
38. Moberly J.B., Attman P.O., Samuelsson O., et al. Alterations in lipoprotein composition in peritoneal dialysis patients. Perit Dial Int 22 (2002) 220-228
39. Castelao A.M., Barbera M.J., Blanco A., et al. Lipid metabolic abnormalities after renal transplantation under cyclosporine and prednisone immunosuppression. Transplant Proc 24 (1992) 96-98
40. Tse K.C., Lam M.F., Yip P.S., et al. A long-term study on hyperlipidemia in stable renal transplant recipients. Clin Transplant 18 (2004) 274-280
41. Kasiske B.L. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 32 (1998) S142-S156
42. Kimak E., and Solski J. Serum lipoprotein(a) concentrations and apolipoprotein(a) phenotypes in hemodialysis, chronic ambulatory peritoneal dialysis and post-transplant patients. Ren Fail 24 (2002) 187-195
43. Brown J.H., Murphy B.G., Douglas A.F., et al. Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation. Nephron 75 (1997) 277-282
44. Fernandez-Miranda C., de la C.A., Morales J.M., et al. Lipoprotein abnormalities in long-term stable liver and renal transplanted patients A comparative study. Clin Transplant 12 (1998) 136-141
45. Quaschning T., Mainka T., Nauck M., et al. Immunosuppression enhances atherogenicity of lipid profile after transplantation. Kidney Int Suppl 71 (1999) S235-S237
46. Artz M.A., Boots J.M., Ligtenberg G., et al. Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus. J Am Soc Nephrol 14 (2003) 1880-1888
47. Chueh S.C., and Kahan B.D. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis. Transplantation 76 (2003) 375-382
48. Morrisett J.D., bdel-Fattah G., Hoogeveen R., et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 43 (2002) 1170-1180
49. Kobashigawa J.A., and Kasiske B.L. Hyperlipidemia in solid organ transplantation. Transplantation 63 (1997) 331-338
50. Berg A.L., and NilssonEhle P. ACTH lowers serum lipids in steroid-treated hyperlipemic patients with kidney disease. Kidney Int 50 (1996) 538-542
51. Mathis A.S., Dave N., Knipp G.T., and Friedman G.S. Drug-related dyslipidemia after renal transplantation. Am J Health Syst Pharm 61 (2004) 565-585
52. Morrisett J.D., bdel-Fattah G., and Kahan B.D. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant Proc 35 (2003) S143-S150
53. Hoogeveen R.C., Ballantyne C.M., Pownall H.J., et al. Effect of sirolimus on the metabolism of apo. Transplantation 72 (2001) 1244-1250
54. Tur M.D., Garrigue V., Vela C., et al. Apolipoprotein CIII is upregulated by anticalcineurins and rapamycin: implications in transplantation-induced dyslipidemia. Transplant Proc 32 (2000) 2783-2784
55. Degoulet P., Legrain M., Reach I., et al. Mortality risk factors in patients treated by chronic hemodialysis Report of the Diaphane collaborative study. Nephron 31 (1982) 103-110
56. Iseki K., Yamazato M., Tozawa M., and Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 61 (2002) 1887-1893
57. Liu Y., Coresh J., Eustace J.A., et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 291 (2004) 451-459
58. Shoji T., Ishimura E., Inaba M., Tabata T., and Nishizawa Y. Atherogenic lipoproteins in end-stage renal disease. Am J Kidney Dis 38 (2001) S30-S33
59. Preston E., Ellis M.R., Kulinskaya E., Davies A.H., and Brown E.A. Association between carotid artery intima-media thickness and cardiovascular risk factors in CKD. Am J Kidney Dis 46 (2005) 856-862
60. Jungers P., Massy Z., Khoa T., et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. Nephrol Dialysis Transplant 12 (1997) 2597-2602
61. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335 (1996) 1001-1009
62. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
63. Briel M., Nordmann A.J., and Bucher H.C. Statin therapy for prevention and treatment of acute and chronic cardiovascular disease: update on recent trials and metaanalyses. Curr Opin Lipidol 16 (2005) 601-605
64. Cannon C.P., Steinberg B.A., Murphy S.A., Mega J.L., and Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 48 (2006) 438-445
65. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
66. Collins R., Armitage J., Parish S., Sleigh P., and Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
67. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
68. Tonelli M., Collins D., Robins S., Bloomfield H., and Curhan G.C. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney Int 66 (2004) 1123-1130
69. Tonelli M., Isles C., Curhan G.C., et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110 (2004) 1557-1563
70. Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 (2005) 238-248
71. Isbel N.M., Haluska B., Johnson D.W., et al. Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function. Am Heart J 151 (2006) 745-753
72. Landray M., Baigent C., Leaper C., et al. The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis 47 (2006) 385-395
73. Holdaas H., Fellstrom B., Jardine A.G., et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 361 (2003) 2024-2031
74. Jardine A.G., Fellstrom B., Logan J.O., et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. Am J Kidney Dis 46 (2005) 529-536
75. Holdaas H., Fellstrom B., Cole E., et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT Extension Study. Am J Transplant 5 (2005) 2929-2936
76. Holdaas H., Fellstrom B., Jardine A.G., et al. Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation. Nephrol Dialysis Transplant 20 (2005) 974-980
77. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
78. Fried L.F., Orchard T.J., and Kasiske B.L. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 59 (2001) 260-269
79. Sandhu S., Wiebe N., Fried L.F., and Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 17 (2006) 2006-2016
80. Athyros V.G., Mikhailidis D.P., Papageorgiou A.A., et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 57 (2004) 728-734
81. Shepherd J., et al. Intensive lipid lowering with atorvastatin is associated with a significant improvement in renal function: the Treating to New Targets (TNT) Study. J Am Coll Cardiol 47 (2006) A316
82. Del C.D., Cruzado J.M., Manel D.J., et al. The effects of hyperlipidaemia on graft and patient outcome in renal transplantation. Nephrol Dial Transplant 19 Suppl. 3 (2004) iii67-iii71
83. Fellstrom B., Holdaas H., Jardine A.G., et al. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney Int 66 (2004) 1549-1555
84. Masterson R., Hewitson T., Leikis M., et al. Impact of statin treatment on 1-year functional and histologic renal allograft outcome. Transplantation 80 (2005) 332-338
85. Ansquer J.C., Foucher C., Rattier S., Taskinen M.R., and Steiner G. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 45 (2005) 485-493
86. Kshirsagar A.V., Shoham D.A., Bang H., et al. The effect of cholesterol reduction with cholestyramine on renal function. Am J Kidney Dis 46 (2005) 812-819
87. Liao J.K. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 96 (2005) 24F-33F
88. Kasiske B., Cosio F.G., Beto J., et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 4 Suppl. 7 (2004) 13-53
89. Schonder K.S., McKaveney T.P., and Lynch K.J. Retrospective analysis of hyperlipidemia management in a transplant population. Pharmacotherapy 25 (2005) 918-923
90. De B.G., Ambrosioni E., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Atherosclerosis 173 (2004) 381-391
91. Erhardt L.R., and Gotto J. The evolution of European guidelines: changing the management of cholesterol levels. Atherosclerosis 185 (2006) 12-20
92. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.5.3. Cardiovascular risks. Hyperlipidaemia. Nephrol Dial Transplant, 2002;17(Suppl. 4):26-8.
93. Tonkin A., Barter P., Best J., et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management-2005. Heart Lung Circ 14 (2005) 275-291
94. Walker R. Cardiovascular risk factors. Nephrology (Carlton) 10 Suppl. 5 (2005) S231-S234
95. Baigent C., and Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl (2003) S207-S210
96. Fellstrom B., Zannad F., Schmieder R., et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients-design and rationale of the AURORA study. Curr Control Trials Cardiovasc Med 6 (2005) 9
97. Kasiske B.L., Wanner C., and O'Neill W.C. An assessment of statin safety by nephrologists. Am J Cardiol 97 (2006) S82-S85
98. Bottorff M.B. Statin safety and drug interactions: clinical implications. Am J Cardiol 97 (2006) S27-S31
99. Broeders N., Knoop C., Antoine M., Tielemans C., and Abramowicz D. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol. Dial Transplant 15 (2000) 1993-1999
100. Lipscombe J., Lewis G.F., Cattran D., and Bargman J.M. Deterioration in renal function associated with fibrate therapy. Clin Nephrol 55 (2001) 39-44
101. Hottelart C., El E.N., Rose F., Achard J.M., and Fournier A. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron 92 (2002) 536-541
102. Kosoglou T., Statkevich P., Johnson-Levonas A.O., et al. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 44 (2005) 467-494
103. Buchanan C., Smith L., Corbett J., Nelson E., and Shihab F. A retrospective analysis of ezetimibe treatment in renal transplant recipients. Am J Transplant 6 (2006) 770-774
104. Simard C., and Poirier P. Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Can J Cardiol 22 (2006) 141-144
105. Knopp R.H. Drug treatment of lipid disorders. N Engl J Med 341 (1999) 498-511
106. Guyton J.R. Extended-release niacin for modifying the lipoprotein profile. Expert Opin Pharmacother 5 (2004) 1385-1398
107. Devaraj S., and Jialal I. The role of dietary supplementation with plant sterols and stanols in the prevention of cardiovascular disease. Nutr Rev 64 (2006) 348-354
108. Psota T.L., Gebauer S.K., and Kris-Etherton P. Dietary omega-3 fatty acid intake and cardiovascular risk. Am J Cardiol 98 (2006) 3-18
109. Davidson M.H. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol 98 (2006) 27-33
110. Robinson J.G., and Stone N.J. Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids. Am J Cardiol 98 (2006) 39-49